Curing cancer is possible. It will happen, it’s just a matter of time, scientific thought, and research funding. The worldwide biomedical research community is collectively studying every aspect of cancer, including cancer cell biology and cancer genomics to develop better methods to prevent cancer, screen for early detection, accurately diagnose patients, and effectively treat patients. Today, February 4th, is World Cancer Day, founded to raise awareness and unite us all in the fight against cancer.
Researchers all over the world are diligently working to help find a cure, and ImmunoChemistry Technologies is no exception. ICT’s line of cell viability assays allows researchers to identify cells in various stage of cell health, including live cells, apoptosis, pyroptosis, necrosis, and autophagy. The ability to accurately identify cell death is extremely important in cancer research, as it allows researchers to determine the efficacy of various drugs or other cancer treatments. These innovative research products have been used by our customers to study how an experimental drug suppresses tumor growth of HCT116 colon cancer cells, the effect of radiation on bone marrow, how a vaccine prevents viruses from turning healthy cells into malignant cells, and how the immune system can be stimulated to attack tumor cells. For example, ICT’s caspase-3/7 reagent was used the study the mechanism of mitomycin (an anti-cancer agent) on EL4 lymphoma cells to determine the best dose to kill tumor cells which could lead to personalized treatments for patients. ICT is continually developing more sensitive reagents to detect dying cells to monitor tumors at their earliest stage. Every experiment and every test puts us one step closer to a cure.
We can all be a part of the cure, one cell at a time! Even if you’re not in the lab, you can still make a big difference by supporting charities and lobbying for government funding of R&D. Unite with ImmunoChemistry Technologies in our common goal to cure cancer. It will happen. #WeCanICan #WorldCancerDay
By Sally Hed, President, ImmunoChemistry Technologies, LLC